Targeting risk factors: a feasible way for prevention of vascular complications in type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-5546
Abstract
The article addresses challenges in the prevention of microvascular complications in type 2 diabetes mellitus (T2DM) and discusses necessity of multifactorial approach to management of these conditions. We present results of a large-scale ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial that elucidates the combined influence of antihypertensive and of intensive glucose-lowering therapy on the risk of development of micro- and macrovascular complications of T2DM
About the Authors
Irina Vladimirovna Kononenko
Endocrinology Research Centre
Russian Federation
Russian Federation
Olga Mikhailovna Smirnova
Endocrinology Research Centre
Russian Federation
Russian Federation
References
1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetesprospective observation study. BMJ. 2000 Aug 12;321(7258):405-412.
2. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S; HOPE investigators. The relationship between dysglycaemia and cardiovascular andrenal risk in diabeticand non-diabetic participants in the HOPE study: a prospective epidemiological analisis. Diabetologia. 2005 Sep;48(9):1749-1755. Epub 2005 Jul 30.
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective stuies. Lancet. 2010 Jun 26;375(9733):2215-2222.
4. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008 Apr;31(4):714-719. Epub 2007 Dec 14.
5. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169.
6. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-2572. Epub 2008 Jun 6.
7. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001 Sep;44(9):1118-1120.
8. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004 Sep 21;141(6):421-431.
9. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006 Jul;152(1):27-38.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-865.
11. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet. 2000 Jan 22;355(9200):253-259.
12. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, Fulcher G, de Galan BE, Harrap S, Hamet P, Heller S, MacMahon S, Marre M, Poulter N, Travert F, Patel A, Neal B, Woodward M; ADVANCE Collaborative Group. Association of HbA1clevels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012 Mar;55(3):636-643. Epub 2011 Dec 21.
13. Hamet P. What matters in ADVANCE and ADVANCE-ON. Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x.
14. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J; ADVANCE Collaborative Group, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009 Nov;32(11):2068-2074. Epub 2009 Aug 3.
15. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J, Colagiuri S, Grobbee DE, Hamet P, Heller S, Neal B, Woodward M; ADVANCE Collaborative Group. Contemporarymodel for cardiovascularriskprediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):393-398. Epub 2011 Feb 28.
Review
For citations:
Kononenko I.V., Smirnova O.M. Targeting risk factors: a feasible way for prevention of vascular complications in type 2 diabetes mellitus. Diabetes mellitus. 2012;15(4):103-108. (In Russ.) https://doi.org/10.14341/2072-0351-5546
Views:
958
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
